Establishing a hybrid remote clinic for patients on biological and targeted synthetic DMARDs in Rheumatology


Because current guidelines (2020-2022) require 6-monthly reviews to ensure ongoing drug efficacy, we were required to see all patients F2F 6-monthly to ascertain if they were doing well or not. Before using the app, there was no efficient way to remotely collect outcome data on our patients before they came to the clinic. Because these novel drugs are so effective, patients on these drugs often have the lowest disease activity of all our cohort, and many of these F2F appointments were unnecessary.

An audit before implementation of the service change showed that in 80% of the F2F appointments, no change was made to medication or treatment plan, suggesting many F2F appointments could be saved by transferring these to remote or virtual appointments.


To develop and deliver, in partnership with patients, a biologics service that uses a hybrid clinic model (F2F and remote) and patient reported outcome measures (using a smartphone app), to guide practice and minimise unnecessary appointments.


Further Findings:

Read more on the NHS website.